Navigation Links
New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow, Stem Cell Transplants
Date:3/18/2008

High-Dose Steroids Delivered Directly to the Organ Successfully Treats

Graft-Versus-Host Disease

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- The standard treatment to treat graft-versus-host disease (GVHD) after bone marrow or cord blood transplant is intravenous (IV) steroids that alter the immune response; however, it is not always effective and failure results in very high mortality. In a study released today, 15 patients who failed standard treatment were given a high dose of steroids directly to the affected organ. By delivering the steroids via catheter to the arteries that are supplying the organs affected by GVHD, a much higher, more effective dose can be given because the rest of the body is spared from the steroid's side effects.

"Overall, fewer than 30 percent of patients with steroid-resistant GVHD respond completely or partially to the standard IV treatment, and their chance of living one year is 15 percent or less. This interventional radiology treatment can be life-saving for these people," said Joshua L. Weintraub, M.D., chief of the Division of Vascular and Interventional Radiology at Mount Sinai Medical Center in New York City.

According to Weintraub, there were no immediate drug or procedure-related complications, and the treatment appears to be safe and effective in combating GVHD -- with about 40 percent of the patients showing complete response to the intra-arterial treatment at less than a year follow-up. The study was presented during the Society of Interventional Radiology's 33rd Annual Scientific Meeting in Washington, D.C.

GVHD is a common complication of an allogeneic bone marrow transplant (one using blood-forming cells donated by a family member or unrelated donor) or cord blood transplant. With GVHD, the immune cells from the donated marrow or cord blood (the graft) attack the body of the transplant patient (the host). GVHD, which can be mild to life-threatening, can affect many different parts of the body, particularly the skin, liver and intestines. In this study the affected organs were the liver and small and large bowels.

Studies from the 1990s show that steroid resistance is common -- 80 percent of people fail to have a sustained, complete response rate or only have a partial response, which means the immune cells are still attacking the organ to varying degrees. "Until now, there has been no good therapy for steroid-resistant patients with GVHD. This small study -- the first of its kind in the United States--shows a new, viable option; however, larger studies with longer follow-up results are needed," added Weintraub.

Abstract 187, "Intra-arterial Steroid Injection Therapy for Systemic Steroid Resistant Graft-Versus-Host Disease," can be found at http://www.SIRmeeting.org.

About Graft-Versus-Host Disease

Graft-versus-host disease (GVHD) is a common side effect of an allogeneic bone marrow transplant (one using blood-forming cells donated by a family member or unrelated donor) or cord blood transplant. The differences between a donor's marrow and recipient's tissues often cause T cells (a type of white blood cell) from the donor's marrow to recognize the recipient's body tissues as foreign, according to the National Institutes of Health. GVHD is the term used when a donor's immune cells attacks the recipient's body -- causing damage. Acute GVHD starts within three months after transplant, while chronic GVHD begins more than three months after transplant (and can last as long as three years). NIH notes that rates of GVHD vary from 30-40 percent for related donors and recipients to 60-80 percent for unrelated donors and recipients. Following a bone marrow transplant, the recipient is prescribed drugs that suppress the immune system to help with reducing the chances or severity of GVHD.

Bone marrow transplants are usually reserved for individuals with life-threatening diseases of the blood, bone marrow or certain types of cancer.

About the Society of Interventional Radiology

Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, usually in an artery, to treat at the source of the disease internally. As the inventors of angioplasty and the catheter-delivered stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern medicine.

Today many conditions that once required surgery can be treated less invasively by interventional radiologists. Interventional radiology treatments offer less risk, less pain and less recovery time compared to open surgery. Visit http://www.SIRweb.org.

Local interviews are available by contacting SIR's communications department at mverrillo@SIRweb.org.


'/>"/>
SOURCE Society of Interventional Radiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SCAI and ACC announce new interventional cardiology meeting
2. Gorilla Receives State-Of-The-Art Treatment for Uterine Fibroids from Interventional Radiologists
3. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
4. Siemens Introduces Its New Generation of Artis Interventional Imaging Systems
5. SCAI Announces New Program to Support Interventional Cardiology Training Fellowships
6. Register Now for Interventional Radiology Meeting Press Conferences
7. AIUM CEO named among most influential in radiology
8. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
9. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
10. Franklin & Seidelmann Enters Full-Service Teleradiology Market with Acquisition of Apex Radiology
11. Radiology Ltd. Chooses AMICAS as End-to-End Solutions Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, had a ... impoverished upbringing and life experiences could have led him down a much different path. ... Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. She ... to become a nun. Now, she writes about God, when she isn’t swimming as a ... and AD, Here is BS! (Before Satan),” she offers a comedic look at the dysfunctions ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from ... scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society ... B. Liegner, M.D. has compiled into a single volume a compelling argument that the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... to announce an upgrade to the company's Yelp listing. Bay Area residents struggling ... as diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... 2011 the lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited ... allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets out ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... The Netherlands , Feb 27, 2017 ... is approved by NATO for use at the security ... security imposed within the NATO organization for the communication of ... ... providing government authorities with an eavesdrop-secure smartphone solution. Sectra Tiger/R ...
(Date:2/24/2017)... February 24, 2017 Following receiving ... Israel , s AMAR is a major ... 250 M w ound care market in ... BST for inclusion in the National Health Basket ...   E-QURE Corp. (OTCQB: EQUR), a leader ...
(Date:2/24/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the Cowen and Company 37 th ... Place on Tuesday, March 7, 2017 at 11:20 a.m. ... the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Medicine Technology: